Background-Beta-2 agonists protect against non-specific bronchoconstricting agents such as methacholine, but it has been suggested that the protection afforded by long acting P)2 agonists wanes rapidly with regular treatment. Methods-The changes in airway responsiveness were investigated during and after eight weeks of regular treatment with salmeterol 50 ug twice daily in 26 adult asthmatic patients, 19 of whom were receiving maintenance inhaled corticosteroids. The study was of a randomised, placebo controlled, double blind design. Airway responsiveness to methacholine was measured as PD,0 by a standardised dosimeter technique 12 hours after the first dose, at four weeks and eight weeks during treatment (12 hours after the last dose of test medication), and at 60 hours, one week and two weeks after stopping treatment. Results-There were no significant differences between the baseline characteristics of the two groups. A significant improvement in PD20 was seen at all points during treatment with salmeterol compared with the placebo group, with no significant fall off with time. PD20 measurements returned to baseline values after cessation of treatment with no significant difference from the placebo group. Conclusions-Salmeterol gave significant protection against methacholine induced bronchoconstriction 12 hours after administration. This protection was of small magnitude, but there was no significant attenuation with eight weeks of regular use and no rebound increase in airway responsiveness on stopping treatment in a group of moderate asthmatic patients, the majority of whom were receiving inhaled corticosteroids.
hours after the last dose of test medication), and at 60 hours, one week and two weeks after stopping treatment. Results-There were no significant differences between the baseline characteristics of the two groups. A significant improvement in PD20 was seen at all points during treatment with salmeterol compared with the placebo group, with no significant fall off with time. PD20 measurements returned to baseline values after cessation of treatment with no significant difference from the placebo group. Conclusions-Salmeterol gave significant protection against methacholine induced bronchoconstriction 12 hours after administration. This protection was of small magnitude, but there was no significant attenuation with eight weeks of regular use and no rebound increase in airway responsiveness on stopping treatment in a group of moderate asthmatic patients, the majority of whom were receiving inhaled corticosteroids. (Thorax 1993; 48: 1121 -1124 There is considerable concern that the regular use of , agonists is associated with a deterioration in asthma control and airway responsiveness. ' The clinical significance of the development of tachyphylaxis to the actions of 82 agonists in this context remains uncertain. It is known that tachyphylaxis to their systemic effects occurs readily,2 but studies of tachyphylaxis to their airway actions of bronchodilation and protection against bronchoconstrictor stimuli have produced conflicting results.34
Salmeterol, a new potent fl2 agonist, has a prolonged duration of action5 so the risk of developing tachyphylaxis with its regular use may be expected to be higher than with the short acting /1, agonists. Studies to date have failed to show any tachyphylaxis to its bronchodilator activity.6 A recent study, however, reported that its protective effect against induced bronchoconstriction may wane with prolonged monotherapy in mild asthmatic patients. 7 The subjects studied, however, had very mild asthma with little or no need for symptomatic relief medication and none had need for prophylactic inhaled steroids.
We have undertaken a placebo controlled study of subjects with mild to moderate asthma, the majority of whom were receiving maintenance inhaled steroid treatment, to assess whether a prolonged course of regular treatment with salmeterol leads to tachyphylaxis of the protective effect against methacholine induced bronchoconstriction at 12 hours after treatment, and exerts any influence on underlying airway responsiveness.
Methods

SUBJECTS
Written informed consent to participate in the study, which had been approved by the Newcastle ethics committee, was obtained from 26 subjects with stable mild to moderate asthma (table 1). All subjects had documented 15% reversibility in peak expiratory flow rate or forced expiratory volume in one second (FEV1) during the run-in period or in the preceding three months. Nineteen subjects were receiving maintenance inhaled corticosteroids up to a maximum equivalent daily dose of 1000 ,ug beclomethasone dipropionate together with salbutamol as "rescue" medication. The remaining seven subjects were receiving salbutamol alone on an as required basis. No subject had received oral steroids in the three months leading up to the study.
MEASUREMENTS
A methacholine test was carried out at each Booth, Fishwick, Harkawat, Devereux, Hendnick, Walters Effect ofsalmeterol on methacholine induced bronchoconstriction METHACHOLINE CHALLENGE TESTS PD20 measurements were significantly higher throughout the treatment period with salmeterol than with placebo, p = 0-01 (figure). This protective effect against methacholine induced bronchoconstriction was seen after the first dose of salmeterol and was maintained without significant change throughout the treatment period, although PD20 measurements on day 56 tended to be slightly lower.
On stopping salmeterol, PD20 measurements returned rapidly to baseline values. There were no significant differences when compared with the placebo group at 60 hours, one week or two weeks after cessation of treatment, although there was a suggestion of some residual protection at 60 hours.
Discussion
This study has shown that salmeterol gives significant protection against methacholine induced bronchoconstriction 12 hours after the first dose compared with placebo. This protective effect is of small magnitude but is maintained during the eight weeks of active treatment with no significant attenuation. After cessation of salmeterol, airway responsiveness returns rapidly to baseline levels with no evidence of a rebound increase.
That no airway tachyphylaxis was shown in this study is in contrast to a recent study by Cheung et al,7 although the designs of the two studies were different. In our study there was no interruption of the regular 12 hourly medication, airway responsiveness being measured just before the next scheduled dose. This is perhaps more reflective of its clinical use. Similarly, if significant attenuation of the protective effect of salmeterol on methacholine induced bronchoconstriction were to develop it might be expected to be more evident at the extreme end of its action-that is, at 12 hours after the last regular dose rather than at one hour after the test dose and after a washout as used by Cheung et agonists is controversial, being described in some4 but not other3 studies. Secondly, we did not have any residual bronchodilation at 12 hours which seems to be a confounder in some studies.'5 This was the case even at the beginning of the study and does not itself represent tachyphylaxis to salmeterol. It is more likely to be a feature of this group of patients with more severe disease. The protection afforded by salmeterol was short lived, and was not significantly different from placebo 60 hours after the last dose. Importantly, however, there was no deterioration in airway responsiveness below baseline values at 60 hours, one week, or two weeks after stopping treatment. This is in agreement with the study by Cheung et al7 and a previous study by our group'6 which found no change in airway responsiveness at 24 hours, 72 hours, and two weeks after stopping six weeks of regular salmeterol or salbutamol. A rebound increase in airway responsiveness may have been missed if it occurred at time points when methacholine testing was not performed. In the study by Vathenan et al'7 which suggested a rebound effect after stopping terbutaline, the maximum difference in measurements of airway responsiveness between terbutaline and placebo groups on cessation of treatment occurred at 23 hours after the last dose-that is, six times the half life of terbutaline. We made measurements at 12 hours and 60 hours after the last dose (5 5 times the half life of salmeterol). These time points were chosen to allow 48 hours between measurements to avoid the confounding problems of refractoriness to methacholine.9 It therefore seems unlikely that any significant rebound increase in airway responsiveness occurs after salmeterol use.
In conclusion, our study was designed to be relevant to the present clinical use of salmeterol. The results of the present study were, therefore, reassuring. We found no evidence of airway tachyphylaxis during eight weeks of regular salmeterol treatment, nor a rebound increase in airway responsiveness on stopping treatment, in a group of patients with mild to moderate asthma.
